EGFR and lung carcinoma: Targeting of AREG has been considered for other cancers, for example AREG siRNAs reduced EGFR activation in hepatocellular carcinoma cell lines and lung cancer cells, which led to decreased growth and increased sensitivity to anti-EGFR targeted therapy [53,54].